MYC is altered in 12.93% of diffuse large B-cell lymphoma patients [3].

MYC is an inclusion criterion in 73 clinical trials for diffuse large B-cell lymphoma, of which 60 are open and 13 are closed. Of the trials that contain MYC status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 21 are phase 1 (15 open), 13 are phase 1/phase 2 (12 open), 25 are phase 2 (20 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (9 open), and 1 is no phase specified (1 open) [4].

MYC is an inclusion criterion in 39 clinical trials for double-hit lymphoma, of which 32 are open and 7 are closed. Of the trials that contain MYC status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (9 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (12 open), 3 are phase 2/phase 3 (2 open), and 4 are phase 3 (4 open) [4].

MYC is altered in 12.98% of diffuse large B-cell lymphoma, not otherwise specified patients [3].

MYC is an inclusion criterion in 33 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 32 are open and 1 is closed. Of the trials that contain MYC status and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 8 are phase 1 (8 open), 6 are phase 1/phase 2 (5 open), 11 are phase 2 (11 open), 1 is phase 2/phase 3 (1 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open) [4].

MYC is an inclusion criterion in 30 clinical trials for triple-hit lymphoma, of which 26 are open and 4 are closed. Of the trials that contain MYC status and triple-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), 3 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open) [4].

MYC is an inclusion criterion in 29 clinical trials for transformed non-hodgkin lymphoma, of which 26 are open and 3 are closed. Of the trials that contain MYC status and transformed non-hodgkin lymphoma as inclusion criteria, 8 are phase 1 (6 open), 8 are phase 1/phase 2 (7 open), 8 are phase 2 (8 open), 1 is phase 2/phase 3 (1 open), and 4 are phase 3 (4 open) [4].

MYC is altered in 11.11% of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements patients [3].

MYC is an inclusion criterion in 24 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 24 are open and 0 are closed. Of the trials that contain MYC status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 5 are phase 1 (5 open), 6 are phase 1/phase 2 (6 open), 7 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (4 open), and 1 is no phase specified (1 open) [4].

MYC is altered in 42.86% of high grade B-cell lymphoma, not otherwise specified patients [3].

MYC is an inclusion criterion in 22 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 21 are open and 1 is closed. Of the trials that contain MYC status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 7 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (9 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [4].

MYC is an inclusion criterion in 18 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 18 are open and 0 are closed. Of the trials that contain MYC status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 4 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 5 are phase 3 (5 open) [4].

MYC is an inclusion criterion in 15 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 14 are open and 1 is closed. Of the trials that contain MYC status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 1/phase 2 (4 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [4].

MYC is an inclusion criterion in 15 clinical trials for grade 3b follicular lymphoma, of which 15 are open and 0 are closed. Of the trials that contain MYC status and grade 3b follicular lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 5 are phase 3 (5 open) [4].

MYC is altered in 11.11% of primary mediastinal B-cell lymphoma patients [3].

MYC is an inclusion criterion in 13 clinical trials for primary mediastinal B-cell lymphoma, of which 13 are open and 0 are closed. Of the trials that contain MYC status and primary mediastinal B-cell lymphoma as inclusion criteria, 6 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [4].

MYC is altered in 2.79% of follicular lymphoma patients [3].

MYC is an inclusion criterion in 13 clinical trials for follicular lymphoma, of which 9 are open and 4 are closed. Of the trials that contain MYC status and follicular lymphoma as inclusion criteria, 7 are phase 1 (3 open), 5 are phase 1/phase 2 (5 open), and 1 is phase 2 (1 open) [4].

MYC is altered in 64.29% of Burkitt lymphoma patients [3].

MYC is an inclusion criterion in 12 clinical trials for Burkitt lymphoma, of which 9 are open and 3 are closed. Of the trials that contain MYC status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (5 open) [4].

MYC is altered in 3.39% of mantle cell lymphoma patients [3].

MYC is an inclusion criterion in 12 clinical trials for mantle cell lymphoma, of which 10 are open and 2 are closed. Of the trials that contain MYC status and mantle cell lymphoma as inclusion criteria, 6 are phase 1 (4 open), 5 are phase 1/phase 2 (5 open), and 1 is phase 2 (1 open) [4].

MYC is altered in 7.91% of B-cell non-hodgkin lymphoma patients [3].

MYC is an inclusion criterion in 10 clinical trials for B-cell non-hodgkin lymphoma, of which 9 are open and 1 is closed. Of the trials that contain MYC status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 5 are phase 1/phase 2 (5 open), and 3 are phase 2 (3 open) [4].

MYC is an inclusion criterion in 10 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 8 are open and 2 are closed. Of the trials that contain MYC status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

MYC is an inclusion criterion in 10 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 10 are open and 0 are closed. Of the trials that contain MYC status and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [4].

MYC is altered in 11.11% of mediastinal large B-cell lymphoma patients [3].

MYC is an inclusion criterion in 9 clinical trials for mediastinal large B-cell lymphoma, of which 7 are open and 2 are closed. Of the trials that contain MYC status and mediastinal large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

MYC is altered in 6.64% of non-hodgkin lymphoma patients [3].

MYC is an inclusion criterion in 9 clinical trials for non-hodgkin lymphoma, of which 6 are open and 3 are closed. Of the trials that contain MYC status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [4].

MYC is altered in 4.85% of malignant solid tumor patients [3].

MYC is an inclusion criterion in 9 clinical trials for malignant solid tumor, of which 4 are open and 5 are closed. Of the trials that contain MYC status and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [4].

MYC is an inclusion criterion in 8 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 8 are open and 0 are closed. Of the trials that contain MYC status and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].

MYC is an inclusion criterion in 8 clinical trials for marginal zone lymphoma, of which 6 are open and 2 are closed. Of the trials that contain MYC status and marginal zone lymphoma as inclusion criteria, 4 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [4].

MYC is an inclusion criterion in 7 clinical trials for ALK-positive large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain MYC status and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [4].

MYC is an inclusion criterion in 7 clinical trials for chronic lymphocytic leukemia, of which 7 are open and 0 are closed. Of the trials that contain MYC status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (2 open) [4].

MYC is an inclusion criterion in 7 clinical trials for germinal center B-cell-like diffuse large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain MYC status and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

MYC is an inclusion criterion in 7 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain MYC status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].

MYC is altered in 9.92% of breast carcinoma patients [3].

MYC is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MYC status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].

MYC is altered in 4.29% of medulloblastoma patients [3].

MYC is an inclusion criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain MYC status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

MYC is altered in 1.82% of hodgkin lymphoma patients [3].

MYC is an inclusion criterion in 6 clinical trials for hodgkin lymphoma, of which 4 are open and 2 are closed. Of the trials that contain MYC status and hodgkin lymphoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

MYC is altered in 1.9% of multiple myeloma patients [3].

MYC is an inclusion criterion in 6 clinical trials for multiple myeloma, of which 3 are open and 3 are closed. Of the trials that contain MYC status and multiple myeloma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

MYC is an inclusion criterion in 5 clinical trials for acute lymphoblastic leukemia, of which 4 are open and 1 is closed. Of the trials that contain MYC status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open) [4].

MYC is an inclusion criterion in 5 clinical trials for diffuse large B-cell lymphoma activated B-cell type, of which 5 are open and 0 are closed. Of the trials that contain MYC status and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is no phase specified (1 open) [4].

MYC is an inclusion criterion in 5 clinical trials for intravascular large B-cell lymphoma, of which 5 are open and 0 are closed. Of the trials that contain MYC status and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].

MYC is altered in 7.33% of ovarian carcinoma patients [3].

MYC is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MYC status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (2 open) [4].

MYC is altered in 5.87% of lymphoma patients [3].

MYC is an inclusion criterion in 4 clinical trials for lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MYC status and lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 4 clinical trials for Richter syndrome, of which 3 are open and 1 is closed. Of the trials that contain MYC status and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [4].

MYC is altered in 4.93% of colorectal carcinoma patients [3].

MYC is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 1 is open and 2 are closed. Of the trials that contain MYC status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [4].

MYC is altered in 4.84% of non-small cell lung carcinoma patients [3].

MYC is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 0 are open and 3 are closed. Of the trials that contain MYC status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [4].

MYC is altered in 2.52% of soft tissue sarcoma patients [3].

MYC is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain MYC status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

MYC is altered in 1.11% of acute myeloid leukemia patients [3].

MYC is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 1 is open and 2 are closed. Of the trials that contain MYC status and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (1 open) [4].

MYC is altered in 1.36% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].

MYC is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MYC status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 3 clinical trials for Burkitt leukemia, of which 3 are open and 0 are closed. Of the trials that contain MYC status and Burkitt leukemia as inclusion criteria, 3 are phase 2 (3 open) [4].

MYC is an inclusion criterion in 3 clinical trials for mature B-cell lymphoma/leukemia, of which 1 is open and 2 are closed. Of the trials that contain MYC status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

MYC is an inclusion criterion in 3 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 3 are open and 0 are closed. Of the trials that contain MYC status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 4 (1 open) [4].

MYC is an inclusion criterion in 3 clinical trials for waldenstrom macroglobulinemia, of which 2 are open and 1 is closed. Of the trials that contain MYC status and waldenstrom macroglobulinemia as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MYC is altered in 5.49% of small cell lung carcinoma patients [3].

MYC is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

MYC is altered in 3.0% of central nervous system embryonal neoplasm patients [3].

MYC is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYC status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYC is altered in 3.79% of pancreatic carcinoma patients [3].

MYC is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

MYC is altered in 2.53% of anaplastic astrocytoma patients [3].

MYC is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].

MYC is altered in 2.32% of head and neck squamous cell carcinoma patients [3].

MYC is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

MYC is altered in 1.61% of glioblastoma patients [3].

MYC is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

MYC is altered in 0.73% of myelodysplastic syndromes patients [3].

MYC is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain MYC status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (1 open) [4].

MYC is altered in 0.7% of gastrointestinal stromal tumor patients [3].

MYC is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain MYC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYC status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYC status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for chronic myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain MYC status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for lymphomatoid granulomatosis, of which 2 are open and 0 are closed. Of the trials that contain MYC status and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain MYC status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

MYC is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain MYC status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for primary central nervous system lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MYC status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 2 clinical trials for small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MYC status and small lymphocytic lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

MYC is altered in 12.5% of large cell/anaplastic medulloblastoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for large cell/anaplastic medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

MYC is altered in 14.29% of vaginal carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MYC is altered in 8.24% of high grade ovarian serous adenocarcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MYC is altered in 8.63% of esophageal adenocarcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is altered in 8.92% of adenocarcinoma of the gastroesophageal junction patients [3].

MYC is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MYC status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is altered in 7.67% of hepatocellular carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is altered in 6.64% of osteosarcoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is altered in 7.91% of mature B-cell non-hodgkin lymphoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 5.87% of prostate carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MYC is altered in 4.17% of penile carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MYC is altered in 5.13% of esophageal squamous cell carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is altered in 4.85% of gastric adenocarcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is altered in 4.72% of solid neoplasm patients [3].

MYC is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYC status and solid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is altered in 4.7% of cancer patients [3].

MYC is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains MYC status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is altered in 4.77% of melanoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 5.93% of endometrial carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is altered in 3.77% of cervical carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MYC is altered in 3.1% of sarcoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 2.65% of biliary tract carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is altered in 3.51% of bladder carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 2.64% of head and neck carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 2.95% of hematopoietic and lymphoid malignancy patients [3].

MYC is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 0 are open and 1 is closed. Of the trial that contains MYC status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (0 open) [4].

MYC is altered in 1.86% of anaplastic oligodendroglioma patients [3].

MYC is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is altered in 1.9% of anal carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MYC is altered in 1.09% of high-grade glioma, NOS patients [3].

MYC is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYC status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is altered in 1.62% of diffuse glioma patients [3].

MYC is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is altered in 1.76% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is altered in 1.61% of malignant glioma patients [3].

MYC is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is altered in 0.9% of leiomyosarcoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is altered in 1.5% of papillary renal cell carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 1.24% of central nervous system neoplasm patients [3].

MYC is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYC status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is altered in 0.68% of clear cell renal cell carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 0.8% of renal cell carcinoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 0.47% of indolent non-hodgkin lymphoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is altered in 0.62% of pleural mesothelioma patients [3].

MYC is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is altered in 0.55% of neuroblastoma patients [3].

MYC is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYC status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-positive, of which 1 is open and 0 are closed. Of the trial that contains MYC status and anaplastic large cell lymphoma, ALK-positive as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains MYC status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MYC status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for Burkitt-like lymphoma with 11q aberration, of which 1 is open and 0 are closed. Of the trial that contains MYC status and Burkitt-like lymphoma with 11q aberration as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for composite lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and composite lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYC status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains MYC status and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains MYC status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MYC status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains MYC status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains MYC status and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for grade 1 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and grade 1 follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for grade 2 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and grade 2 follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for grade 3 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and grade 3 follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for hairy cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC status and hairy cell leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for intraocular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and intraocular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for large B-cell lymphoma with IRF4 rearrangement, of which 1 is open and 0 are closed. Of the trial that contains MYC status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYC status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is an inclusion criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains MYC status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains MYC status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYC is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for plasmablastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and plasmablastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and small intestinal lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYC is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].